Preclinical services

Robust standard and custom-designed in vitro models to respond to customers’ specific requirements

Therapeutic areas

Alzheimer’s Disease

Primary culture of cortical neurons or primary culture of hippocampal neurons
• 1-42 Beta amyloid peptide injuries (injuries induced with oligomers of peptide, for information see Callizot et al., 2013)
• Glutamate and NMDA injuries
• TNF alpha injuries

Huntington’s Disease

Primary culture of mesencephalic neurons
• Glutamate injuries
• Growth factor deprivation

Peripheral neuropathies

Primary culture of sensory neurons (for information see Callizot et al., 2008)
Myelinating co-culture of Schwann cells and sensory neurons (for information see Callizot et al., 2011)
• Taxol injuries
• Cisplatine injuries
• Vincristine injuries
• Pharmacological demyelination

Blood Brain Barrier model (penetrance of molecule)

• Model of BBB to assess on the BBB penetrance of molecule in the CNS
• Under healthy condition or pathological conditions (AD, PD or stress conditions)

Parkinson’s Disease

Primary culture of mesencephalic neurons (for information see Visanji et al., 2008)
• 6-hydroxydopamine injuries
• MPP+ injuries
• Rotenone injuries
• α-synuclein injuries (ref. AD/PD poster Callizot et al., 2015)

Multiple Sclerosis

Full brain
Myelinating co-culture of oligodendrocytes and central neurons
• Pharmacological demyelination

Amyotrophic Lateral Sclerosis

Nerves / muscle co-culture (for information see Braun et al., 1995 ; 1996)
or primary culture of motorneurons (for information see Guettier-Sigrist et al., 2001)
• Glutamate injuries
• 1-42 Beta amyloid peptide injuries (for information see Combes et al., 2014)

CNS Preclinical services

Primary nerve cell culture

Primary nerve cell cultures are powerful models that we use to evaluate the responses of target cells at the cellular and molecular levels to the deleterious effects of neurotoxic substances or neuroprotective effects. Primary cultures of nerve cells are prepared from either fetal or new born rat brains, cultured with specific media. By using cells with different days-in-culture it is possible to mimic and evaluate developmental-related modifications.

Cell based assays

At Neuro-Sys, we support clients’ projects by designing dedicated cell-based assays on neurodegenerative diseases. Our assays based on primary cultures of neurons have been highly improved and miniaturized to 96 well plates increasing the number of conditions per plate and decreasing the study times and costs compared to in vivo testing.

Pharmacological profiling and mode of action studies

Platforms developed by Neuro-Sys provide large, automated and standardized screening of molecules. The Neuro-Sys SCREENSIMPLE® process allows simultaneous testing up to 7 concentrations on integrated systems (different from the classic MTS : Medium Throughput Screening) in validated neurodegenerative diseases in vitro models.

Mainly based on primary cell cultures, our SCREENSIMPLE® process composed of two platforms allows a fast, efficient and advanced screening assay solution :
E-FORM® : Neuro-Efficacy MTS Platform which allows the screening of thousands of molecules per year providing a complete pharmacological evaluation (dose ranging, how the test compound works and on which cells) and the main pathway involved in the efficacy of the molecule, all into a single screening.

MOAFORM® : Mode Of Action Platform which allows us to define the targeted protein and/or RNA.

The Neuro-Sys ECO-SIPLEX® process combines the SCREENSIMPLE® process with the GREEN-FORM® platform in order to define the pharmacological profiling and underlying mechanism of action of a plant extract or a natural product lead compound.
GREEN-FORM® : This platform allows the green-extraction and characterization of lead compound embedded in natural products or plant extracts.
Our own modern laboratory focused on the green-extraction of natural products uses the latest extraction techniques notably based on micro waves and ultrasound technologies and doesn’t involve any solvents potentially harmful to humans or the environment.

Drug Discovery Advisory

Our experts also travel to client companies to support them as needed (internal meetings, conferences…). They can provide expertise and advice regarding the client’s technical development, drug discovery and drug development strategies, and even decision making.